Summary of Significant Accounting Policies - Additional Information (Details)		1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 25, 2022 USD ($) Market	Dec. 31, 2022	Jun. 30, 2022 USD ($) Institution	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) Market ReportingUnits Segment Institution	Jun. 30, 2021 USD ($)
Segment and Geographic Information
Number of operating segments | Segment					1
Cash Equivalents
Cash Equivalents			$ 73,400,000		$ 73,400,000
Concentration of Credit Risk
Number of financial institutions that hold the Company's cash | Institution			1		1
Business Combination
Intangible assets, Estimated period of benefit					10 years
Number of reporting units | ReportingUnits					1
Accounts Receivable, net
Accounts receivable, Allowance for credit loss			$ 0		$ 0
Equipment, net
Estimated useful life					3 years
Cost of Product Sales
Cost of product sales			$ 1,000,000.0	$ 1,000,000.0	$ 0	$ 0
Sales				$ 0		0
Income Taxes
Income tax benefit					$ 0	$ 0
Sunosi
Cost of Product Sales
Number of Asian markets | Market					12
Revenue milestones	$ 165,000,000				$ 165,000,000
Development milestones	$ 1,000,000				$ 1,000,000
Jazz Pharmaceuticals Plc | Sunosi
Business Combination
Intangible assets, Estimated period of benefit					10 years
Cost of Product Sales
Number of Asian markets | Market	12
2014-09
Recent Accounting Pronouncements
Change in accounting principle, accounting standards update, adopted			true		true
Change in accounting principle, accounting standards update, adoption date			Jan. 01, 2018		Jan. 01, 2018
Change in accounting principle, accounting standards update, immaterial effect			true		true
Forecast
Income Taxes
Effective tax rate		0.00%